These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 17017519)

  • 21. Role of iron in UPS impairment model of Parkinson's disease.
    Le W
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S158-61. PubMed ID: 24262171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of the direct and indirect effects of MPP+ and dopamine on the human proteasome: implications for Parkinson's disease aetiology.
    Caneda-Ferrón B; De Girolamo LA; Costa T; Beck KE; Layfield R; Billett EE
    J Neurochem; 2008 Apr; 105(1):225-38. PubMed ID: 18021296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p-Quinone mediates 6-hydroxydopamine-induced dopaminergic neuronal death and ferrous iron accelerates the conversion of p-quinone into melanin extracellularly.
    Izumi Y; Sawada H; Sakka N; Yamamoto N; Kume T; Katsuki H; Shimohama S; Akaike A
    J Neurosci Res; 2005 Mar; 79(6):849-60. PubMed ID: 15712215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease.
    Xie W; Li X; Li C; Zhu W; Jankovic J; Le W
    J Neurochem; 2010 Oct; 115(1):188-99. PubMed ID: 20649845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuromelanin-bound ferric iron as an experimental model of dopaminergic neurodegeneration in Parkinson's disease.
    Gerlach M; Riederer P; Double KL
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S185-8. PubMed ID: 18585086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease.
    McNaught KS; Jnobaptiste R; Jackson T; Jengelley TA
    Synapse; 2010 Mar; 64(3):241-50. PubMed ID: 19924695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Saturation Binding of Nicotine to Synthetic Neuromelanin Demonstrated by Fluorescence Spectroscopy.
    Haining RL; Jones TM; Hernandez A
    Neurochem Res; 2016 Dec; 41(12):3356-3363. PubMed ID: 27662849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis.
    Jiang H; Ren Y; Zhao J; Feng J
    Hum Mol Genet; 2004 Aug; 13(16):1745-54. PubMed ID: 15198987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuromelanin in Parkinson's Disease: from Fenton Reaction to Calcium Signaling.
    Knörle R
    Neurotox Res; 2018 Feb; 33(2):515-522. PubMed ID: 28879408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.
    Jellinger KA
    Drugs Aging; 1999 Feb; 14(2):115-40. PubMed ID: 10084365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70.
    Mandel S; Grunblatt E; Riederer P; Amariglio N; Jacob-Hirsch J; Rechavi G; Youdim MB
    Ann N Y Acad Sci; 2005 Aug; 1053():356-75. PubMed ID: 16179542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A mechanistic study of proteasome inhibition-induced iron misregulation in dopamine neuron degeneration.
    Li XP; Xie WJ; Zhang Z; Kansara S; Jankovic J; Le WD
    Neurosignals; 2012; 20(4):223-36. PubMed ID: 22269801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of iron in senescence of dopaminergic neurons in Parkinson's disease.
    Youdim MB; Riederer P
    J Neural Transm Suppl; 1993; 40():57-67. PubMed ID: 8294901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuromelanin Modulates Heterocyclic Aromatic Amine-Induced Dopaminergic Neurotoxicity.
    Lawana V; Um SY; Rochet JC; Turesky RJ; Shannahan JH; Cannon JR
    Toxicol Sci; 2020 Jan; 173(1):171-188. PubMed ID: 31562763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell death of dopamine neurons in aging and Parkinson's disease.
    Naoi M; Maruyama W
    Mech Ageing Dev; 1999 Nov; 111(2-3):175-88. PubMed ID: 10656535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells.
    Shamoto-Nagai M; Maruyama W; Kato Y; Isobe K; Tanaka M; Naoi M; Osawa T
    J Neurosci Res; 2003 Nov; 74(4):589-97. PubMed ID: 14598303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson's disease rat model.
    Inden M; Taira T; Kitamura Y; Yanagida T; Tsuchiya D; Takata K; Yanagisawa D; Nishimura K; Taniguchi T; Kiso Y; Yoshimoto K; Agatsuma T; Koide-Yoshida S; Iguchi-Ariga SM; Shimohama S; Ariga H
    Neurobiol Dis; 2006 Oct; 24(1):144-58. PubMed ID: 16860563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mitochondrial complex I inhibitor rotenone-elicited dopamine redistribution from vesicles to cytosol in human dopaminergic SH-SY5Y cells.
    Watabe M; Nakaki T
    J Pharmacol Exp Ther; 2007 Nov; 323(2):499-507. PubMed ID: 17726156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopaminergic neurons.
    Chinta SJ; Andersen JK
    Int J Biochem Cell Biol; 2005 May; 37(5):942-6. PubMed ID: 15743669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Iron metabolism and Parkinson's disease.
    Hirsch EC; Faucheux BA
    Mov Disord; 1998; 13 Suppl 1():39-45. PubMed ID: 9613717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.